Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
Suppressor-cell dysfunction in children with histiocytosis-X
β Scribed by B. T. Shannon; W. A. Newton
- Book ID
- 105003530
- Publisher
- Springer
- Year
- 1986
- Tongue
- English
- Weight
- 1021 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0271-9142
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. Manifestations of Langerhans cell histiocytosis (LCH) in children range from only a rash, to bony lesions accompanied by pain, to major organ disease. When the central nervous system (CNS) is affected, the LCH patient may exhibit signs and symptoms of hypothalamic and pituitary dysfuncti
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt